Cargando…
The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
Tumour progression and therapy resistance in squamous cell carcinoma of the skin (SCC) is strongly associated with resistance to intrinsic mitochondrial apoptosis. We thus investigated the role of various anti-apoptotic Bcl-2 proteins for apoptosis protection in SCC using the BH3 agonist ABT737 that...
Autores principales: | Geserick, P, Wang, J, Feoktistova, M, Leverkus, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540197/ https://www.ncbi.nlm.nih.gov/pubmed/25210795 http://dx.doi.org/10.1038/cddis.2014.379 |
Ejemplares similares
-
The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015) -
Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014) -
Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
por: Zall, Henry, et al.
Publicado: (2010) -
A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML
por: Wang, Qing, et al.
Publicado: (2019) -
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)